Patients with extensive-stage small cell lung cancer (ES-SCLC) who receive trilaciclib appear to experience lower rates of hematologic adverse effects than those who are not treated with the agent.
A phase 3 trial found that testosterone recovery after androgen deprivation therapy leads to better quality of life following high-risk prostate cancer.
RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2023 G1 Therapeutics, Inc. , a commercial-stage oncology company, today announced the presentation of four posters that provide new-real world evidence.
G1 Therapeutics (GTHX) Reports Data Showing Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with ES-SCLC streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Integra Connect, LLC., the leading provider of value-based, precision medicine solutions and services for specialty care, today announced.